GlassScriptPhysician profile
Phillip Painley
NPI 1922165711
$9,754.79
in general payments reported to CMS, 2019-2025
41 companies · $2,447 in 2025
The $2,447 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,601 · 2020: $337 · 2021: $372 · 2022: $427 · 2023: $1,200 · 2024: $2,369 · 2025: $2,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,928 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,928.06 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,706.12 | 2019-2025 | Lifevest |
| Amgen INC. | $1,293.77 | 2019-2025 | Repatha, Repatha, Evenity |
| Medtronic, INC. | $1,021.17 | 2022-2025 | Resolute Onyx, Symplicity G3, Euphora |
| Novartis Pharmaceuticals Corporation | $933.22 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $522.35 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Janssen Pharmaceuticals, INC | $457.26 | 2019-2024 | Xarelto |
| Abiomed | $413.51 | 2022-2025 | Impella |
| Elutia, INC. | $404.71 | 2019-2020 | |
| Pfizer INC. | $342.02 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.84 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $249.32 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Actelion Pharmaceuticals US, INC. | $237.11 | 2019-2024 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $209.96 | 2023-2025 | Camzyos, Eliquis |
| Terumo Medical Corporation | $160.99 | 2024-2025 | Tr Band, Glidewire |
| Bayer Healthcare Pharmaceuticals INC. | $157.69 | 2024-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $124.87 | 2021-2025 | Indigo System |
| Boston Scientific Corporation | $116.87 | 2019-2025 | Wolverine Coronary Cutting Balloon, Rotablator Rotational Atherectomy System Console Kit, Watchman Flx |
| Impulse Dynamics (USA) INC. | $104.23 | 2022-2025 | Optimizer |
| Tactile Systems Technology INC | $103.41 | 2024 | Entre Plus, Flexitouch Plus |
| Sanofi-Aventis U.S. LLC | $87.04 | 2019-2023 | |
| Amarin Pharma, INC. | $84.56 | 2019-2021 | |
| Abbott Laboratories | $77.78 | 2019-2024 | Xience Skypoint |
| Acist Medical Systems, INC. | $75.53 | 2023-2025 | |
| Shockwave Medical, INC | $67.54 | 2023-2024 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Chiesi USA, INC. | $58.08 | 2022-2024 | Kengreal, Cleviprex |
| Lantheus Medical Imaging, INC. | $47.05 | 2019 | |
| Heartflow, INC. | $38.88 | 2025 | |
| Gilead Sciences, INC. | $33.29 | 2019 | |
| Cvrx, INC. | $32.92 | 2023 | Barostim Neo System |
| Teleflex LLC | $28.71 | 2025 | Twin-Pass |
| Allergan, INC. | $26.91 | 2019-2021 | |
| Angiodynamics, INC. | $26.82 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $26.11 | 2019-2025 | Evkeeza |
| Cleerly, INC. | $24.65 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Irhythm Technologies, INC. | $23.75 | 2024 | Zio Xt Patch, Zio Monitor |
| Hikma Pharmaceuticals USA | $18.72 | 2019 | |
| Esperion Therapeutics, INC. | $18.62 | 2025 | Nexletol |
| Ekos Corporation | $18.48 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $18.33 | 2024 | |
| Cardiovascular Systems INC. | $14.19 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $13.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Painley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.